Loading...
Market
Story
FDA Authorizes Updated Novavax COVID-19 Vaccine for Ages 12 and Older
Aug 30, 2024, 06:43 PM
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization for an updated Novavax COVID-19 vaccine. This vaccine is authorized for individuals aged 12 years and older. The updated vaccine is designed to more closely target currently circulating variants, aiming to provide better protection against serious outcomes of COVID-19, such as hospitalization and death. This authorization offers an alternative to mRNA vaccines, expanding the options available for COVID-19 vaccination.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Yes • 50%
No • 50%
High (>70%) • 25%
Moderate (50-70%) • 25%
Low (30-50%) • 25%
Very Low (<30%) • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
0-17 years • 25%
18-49 years • 25%
50-64 years • 25%
65+ years • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%